Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: FICO stock price vs VNDA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VNDA's multiple
Needs VNDA P/E.
Implied fair value · at FICO's multiple
Needs EPS (TTM) is negative, FICO P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: FICO FY 2025 (ended Sep 30, 2025) · VNDA FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
FAIR ISAAC CORP · implied price per share
Bear
$228.31
Base
$268.61
Bull
$308.90
VANDA PHARMACEUTICALS INC. · implied price per share
Bear
-$5.92
Base
-$6.96
Bull
-$8.01
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
-1.98x
0.24x
Net debt / EBITDA
Leverage against operating earnings
3.19x
0.82x
Cash and equivalents
Liquid reserves on the balance sheet
$156.14M
$185.77M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
MSCI Inc.
FICO vs MSCI
MOODYS CORP /DE/
FICO vs MCO
SS&C Technologies Holdings Inc
FICO vs SSNC
Verisk Analytics, Inc.
FICO vs VRSK
EQUIFAX INC
FICO vs EFX
SUPERNUS PHARMACEUTICALS, INC.
FICO vs SUPN
CATALYST PHARMACEUTICALS, INC.
FICO vs CPRX
Harmony Biosciences Holdings, Inc.
FICO vs HRMY
ELI LILLY & Co
FICO vs LLY
INCYTE CORP
FICO vs INCY
Sarepta Therapeutics, Inc.
FICO vs SRPT
$3.46B
$78.18M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
